These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12201624)

  • 1. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany.
    Zacher J; Schattenkirchner M
    Curr Med Res Opin; 2002; 18(4):229-36. PubMed ID: 12201624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
    Collantes-Estevez E; Fernandez-Perez C
    Curr Med Res Opin; 2003; 19(5):402-10. PubMed ID: 13678477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study.
    Arboleya LR; de la Figuera E; Soledad García M; Aragón B;
    Curr Med Res Opin; 2003; 19(4):288-97. PubMed ID: 12841921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey.
    Steinfeld S; Poriau S
    Curr Med Res Opin; 2001; 17(2):81-7. PubMed ID: 11759186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
    Day R; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit KB; Kress B; Daniels B; Bolognese J; Krupa D; Seidenberg B; Ehrich E
    Arch Intern Med; 2000 Jun; 160(12):1781-7. PubMed ID: 10871971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
    Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP;
    Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
    Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
    Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
    JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis.
    Herrera JA; González M
    Am J Ther; 2003; 10(6):468-72. PubMed ID: 14624289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rofecoxib improves quality of life in patients with hip or knee osteoarthritis.
    Theiler R; Bischoff HA; Good M; Uebelhart D
    Swiss Med Wkly; 2002 Nov; 132(39-40):566-73. PubMed ID: 12571763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
    Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
    MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
    Saag K; van der Heijde D; Fisher C; Samara A; DeTora L; Bolognese J; Sperling R; Daniels B
    Arch Fam Med; 2000; 9(10):1124-34. PubMed ID: 11115219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
    Kivitz AJ; Greenwald MW; Cohen SB; Polis AB; Najarian DK; Dixon ME; Moidel RA; Green JA; Baraf HS; Petruschke RA; Matsumoto AK; Geba GP;
    J Am Geriatr Soc; 2004 May; 52(5):666-74. PubMed ID: 15086644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.
    Pellissier JM; Straus WL; Watson DJ; Kong SX; Harper SE
    Clin Ther; 2001 Jul; 23(7):1061-79. PubMed ID: 11519771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
    Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
    Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
    Cannon GW; Caldwell JR; Holt P; McLean B; Seidenberg B; Bolognese J; Ehrich E; Mukhopadhyay S; Daniels B
    Arthritis Rheum; 2000 May; 43(5):978-87. PubMed ID: 10817549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.